Stifel Nicolaus Cuts Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.25

Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective cut by Stifel Nicolaus from $1.50 to $1.25 in a report issued on Tuesday morning,Benzinga reports. They currently have a hold rating on the stock.

Bolt Biotherapeutics Stock Down 0.1 %

Shares of NASDAQ BOLT opened at $0.44 on Tuesday. The stock has a market cap of $16.82 million, a P/E ratio of -0.26 and a beta of 0.94. The business’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $0.55. Bolt Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.56. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.79 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. As a group, equities analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC purchased a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at about $42,000. Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics in the fourth quarter valued at approximately $27,000. Squarepoint Ops LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter valued at approximately $26,000. Millennium Management LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter worth approximately $25,000. Finally, FMR LLC raised its holdings in Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after purchasing an additional 28,773 shares in the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.